Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

Phase 1positiveVY1706Positive

AI Analysis

Summary

Voyager announced that VY1706 demonstrated good tolerability and tau reduction in a 6-month GLP toxicology study, with clinical trial initiation in Alzheimer's Disease expected in H2 2026. Data were presented as a poster at AAIC 2026.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Single IV dose well tolerated, reduced tau in 6-month GLP toxicology study

Importance:6/10

Sentiment:

0.70

Alzheimer's Diseasetau reductiontoxicology studyclinical trial initiationAAIC 2026

Related Companies

$VYGR

Read the original article

Published by GlobeNewswire Clinical Studies on July 13, 2026 12:01 PM

Read Original